Cost of Revenue Comparison: Biogen Inc. vs Xenon Pharmaceuticals Inc.

Cost of Revenue: Biogen Inc. vs. Xenon Pharmaceuticals Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis compares the cost of revenue for Biogen Inc. and Xenon Pharmaceuticals Inc. from 2014 to 2023. Biogen, a leader in biotechnology, consistently shows a robust cost of revenue, peaking at approximately $2.5 billion in 2023, marking a 116% increase from 2014. In contrast, Xenon Pharmaceuticals, a smaller player, has seen its cost of revenue grow significantly, from around $5.9 million in 2014 to $167 million in 2023, a staggering 2,730% increase. This growth reflects Xenon's expanding operations and market presence. While Biogen's costs are higher, Xenon's rapid growth rate is noteworthy. This comparison highlights the diverse financial landscapes within the pharmaceutical sector, offering insights into strategic growth and operational efficiency.